Table 3.

Cox regression analysis examining the relation of proteins with incident atrial fibrillation

	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
	Model 1		Model 2		Model 3
NT-proBNP	1.95 (1.75 to 2.19)	5.1×10–32	1.80 (1.60 to 2.04)	3.2×10–21	1.80 (1.58 to 2.04)	1.2×10–19
OPN	1.38 (1.22 to 1.56)	4.2×10–7	1.27 (1.12 to 1.44)	2.2×10–4	1.27 (1.12 to 1.44)	2.7×10–4
MMP-2	1.29 (1.14 to 1.47)	6.6×10–5	1.20 (1.21 to 1.84)	0.004	1.22 (1.07 to 1.39)	0.002
IGFBP-7	1.27 (1.12 to 1.43)	1.2×10–4	1.18 (1.05 to 1.33)	0.007	1.15 (1.02 to 1.29)	0.026
UPAR	1.30 (1.15 to 1.47)	3.7×10–5	1.20 (1.05 to 1.36)	0.006	1.16 (1.02 to 1.32)	0.028
FABP4	1.27 (1.13 to 1.44)	8.6×10–5	1.36 (1.19 to 1.55)	9.0×10–6	1.14 (0.98 to 1.32)	0.098
GDF-15	1.41 (1.25 to 1.59)	9.7×10–9	1.22 (1.07 to 1.38)	0.003	1.141 (0.97 to 1.27)	0.126
GAL-4	1.30 (1.15 to 1.47)	3.5×10–5	1.21 (1.07 to 1.37)	0.003	1.09 (0.95 to 1.24)	0.220
CHI3L1	1.26 (1.12 to 1.43)	1.4×10–4	1.15 (1.02 to 1.30)	0.021	1.07 (0.95 to 1.22)	0.257
TNFR1	1.26 (1.12 to 1.42)	1.6×10–4	1.14 (1.01 to 1.29)	0.035	1.07 (0.94 to 1.21)	0.297
PON3	0.80 (0.72 to 0.89)	7.3×10–5	0.82 (0.73 to 0.92)	0.001	0.94 (0.83 to 1.11)	0.298

Values are HRs and 95% CI for incident atrial fibrillation. Model 1 is unadjusted. Model 2 is age and sex adjusted. Model 3 is further adjusted for body mass index, systolic blood pressure, smoking status, prevalent diabetes mellitus, prevalent coronary events, prevalent heart failure and antihypertensive treatment.

CHI3L1, chitinase-3-like protein 1; FABP4, fatty-acid binding protein 4; GAL-4, galectin 4; GDF-15, growth differentiation factor 15; IGFBP-7, insulin-like growth factor-binding protein 7; MMP-2, matrix metalloproteinase-2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OPN, osteopontin; PON3, paraoxonase 3; TNFR1, tumour necrosis factor receptor 1; UPAR, urokinase receptor.